Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Obsidian Therapeutics Q3 EPS $(1.23) Up From $(14.77) YoY
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
Obsidian Therapeutics shares are trading higher after the company announced updated results in patients with immune-checkpoint inhibitor-resistant advanced melanoma from the Phase 1 single-center first-in-human study and the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel.
Obsidian Therapeutics To Present Updated Data In Participants With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Phase 1 Trial, Phase 1/2 Agni-01 Multicenter Trial Of Amsokigene Autoleucel At Society For Immunotherapy Of Cancer
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucel
Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error
Obsidian Therapeutics Files Prospectus Related To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockholders
Obsidian Therapeutics (OBX) Stock Dropped, So What Is Behind The Attention Now?
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma
Piper Sandler Initiates Coverage On Obsidian Therapeutics with Overweight Rating, Announces Price Target of $42
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.